Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | ARID1A dec exp |
Therapy | Dactolisib |
Indication/Tumor Type | urinary bladder cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ARID1A dec exp | urinary bladder cancer | sensitive | Dactolisib | Preclinical - Cell culture | Actionable | In a preclinical study, Dactolisib (BEZ235) inhibited viability of bladder cancer cell lines with ARID1A knockdown in culture (PMID: 35852858). | 35852858 |
PubMed Id | Reference Title | Details |
---|---|---|
(35852858) | ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitors. | Full reference... |